Normal-Organ Effective Half-Lives for 177Lu-PSMA
To report effective half-lives of normal organs and investigate the relationship between kidney effective half-life and creatinine clearance in patients undergoing 177Lu-PSMA-617 therapy at our institution. As single-timepoint dosimetry relies on patient-kine...
Poster Program · Radiopharmaceuticals, Theranostics, and Nuclear Medicine
Presenting AuthorPosterBRP-30
Despite the widespread use of Lu-177-PSMA for treatment of prostate cancer, the association between renal dose and toxicity remains unclear. This study investigates this relationship.
Poster Program · Radiopharmaceuticals, Theranostics, and Nuclear Medicine